Who are Agenerase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vivjoa, Viracept, Diflucan, Versed, Xanax, Pyrazinamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amprenavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Agenerase — Competitive Intelligence Brief

Agenerase (AMPRENAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease Inhibitor. Area: Immunology.

marketed Protease Inhibitor Cytochrome P450 3A4 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Agenerase (AMPRENAVIR) — GSK.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Agenerase TARGET	AMPRENAVIR	GSK	marketed	Protease Inhibitor	Cytochrome P450 3A4	1999-01-01
Vivjoa	OTESECONAZOLE	Mycovia Pharms	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	2022-01-01
Viracept	NELFINAVIR	Agouron Pharms	marketed	Protease Inhibitor	Cytochrome P450 3A4	1997-01-01
Diflucan	Fluconazole	Pfizer	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	1990-01-01
Versed	midazolam	Generic (originally Roche)	marketed	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Xanax	alprazolam	Generic (originally Upjohn/Pfizer)	marketed	Benzodiazepine (triazolobenzodiazepine)	Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4	1981-10-16
Pyrazinamide	PYRAZINAMIDE	Dava Pharms Inc	marketed	Antimycobacterial [EPC]	Cytochrome P450 3A4	1971-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-01-18 — Versed · 9687495 · Formulation · US
2028-01-18 — Versed · 9289432 · Formulation · US
2028-01-18 — Versed · 8217033 · Formulation · US
2028-01-18 — Versed · 8809322 · Formulation · US
2038-06-20 — Versed · 10966990 · Formulation · US

Sponsor landscape (Protease Inhibitor class)

GSK · 2 drugs in this class
Agouron Pharms · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Agenerase — Competitive Intelligence Brief. https://druglandscape.com/ci/amprenavir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab